Impact of Serum Adiponectin Concentration on Progression of Carotid Atherosclerosis in Patients with Type 2 Diabetes Mellitus.
- Author:
Chul Sik KIM
1
;
Ju Ri PARK
;
Sung Hoon YU
;
Jun Goo KANG
;
Ohk Hyun RYU
;
Seong Jin LEE
;
Eun Gyung HONG
;
Doo Man KIM
;
Jae Myung YOO
;
Sung Hee IHM
;
Moon Gi CHOI
;
Hyung Joon YOO
Author Information
- Publication Type:Original Article
- Keywords: Adiponectin; Carotid atherosclerosis; Carotid intima media thickness; Type 2 diabetes mellitus
- MeSH: Adiponectin; Ambulatory Care Facilities; Atherosclerosis; Cardiovascular Diseases; Carotid Artery Diseases; Carotid Intima-Media Thickness; Cause of Death; Cholesterol, LDL; Diabetes Mellitus, Type 2; Follow-Up Studies; Humans; Prospective Studies; Risk Factors
- From:Endocrinology and Metabolism 2012;27(1):31-38
- CountryRepublic of Korea
- Language:Korean
- Abstract: BACKGROUND: Increased cardiovascular events, which is the leading cause of death in type 2 diabetic patients, are mainly caused by accelerated atherosclerosis. Adiponectin has been suggested as a risk factor for cardiovascular diseases in cross-sectional studies. However, little is known about the impact of adiponectin on the progression of carotid atherosclerosis in type 2 diabetic patients. This study was conducted to evaluate the impact of early adiponectin levels on the progression of carotid atherosclerosis. METHODS: From March 2009, 150 patients with type 2 diabetes were consecutively enrolled in our affiliated outpatient clinic. Anthropometric and biochemical data, including adiponectin levels, were measured in each participant. We measured the carotid intima-media thickness (CIMT) at baseline and at 1-year follow-up (n = 111). Then, we prospectively studied the relationship between the serum adiponectin levels and the progression of CIMT for 1 year. RESULTS: Adiponectin levels negatively correlated with CIMT (r = -0.219, P = 0.015). Moreover, mean progression of CIMT was 0.016 +/- 0.040 mm. However, there was no correlation between adiponectin levels and the progression of CIMT within 1-year follow-up period (r = -0.156, P = 0.080). Age (beta = 0.556, P = 0.004), LDL cholesterol (beta = 0.276, P = 0.042), and A1C (beta = 0.309, P = 0.038) were found to be independent risk factors for CIMT. However, A1C (beta = 0.311, P = 0.042) was found to be the only independent risk factor for the progression of CIMT. CONCLUSION: In our study, adiponectin levels were negatively associated with CIMT. However, it did not affect the progression of CIMT at 1-year follow-up. Overall glycemic control is the most important factor in the progression of CIMT in patients with type 2 diabetes.
